Next Article in Journal
miR-542-3p Attenuates Bone Loss and Marrow Adiposity Following Methotrexate Treatment by Targeting sFRP-1 and Smurf2
Next Article in Special Issue
Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy
Previous Article in Journal
Quantum Artificial Neural Network Approach to Derive a Highly Predictive 3D-QSAR Model for Blood–Brain Barrier Passage
Previous Article in Special Issue
Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 20
10.3390/ijms222010996
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Zika Virus: A New Therapeutic Candidate for Glioblastoma Treatment

Int. J. Mol. Sci. 2021, 22(20), 10996; https://doi.org/10.3390/ijms222010996
by Maria Giovanna Francipane 1,2,†, Bruno Douradinha 1,3,†, Cinzia Maria Chinnici 1,3, Giovanna Russelli 3, Pier Giulio Conaldi 3 and Gioacchin Iannolo 3,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2021, 22(20), 10996; https://doi.org/10.3390/ijms222010996
Submission received: 29 July 2021 / Revised: 29 September 2021 / Accepted: 9 October 2021 / Published: 12 October 2021
(This article belongs to the Special Issue Frontiers in Neuro-Oncology)

Round 1

Reviewer 1 Report

The paper by Francipane et all describes molecular biology of Zika virus from translational perspective in neuro-oncology. I think it is a well-written paper which deserves to be published. Despite a high octane value of this topic I think authors should convey some message across this paper 1.As stated at the end there are about 20 ongoing clinical trials using oncolytic viruses and it will be great if authors prepare the own-designed table 2.NSC and CSC share several molecular characteristics which prevent Zika to selective infect. That need to be stressed out more clear unless existence of mechanism that prompt Zika virus to distinguish healthy cells from neoplastic cells 3. Topic of ZIka persistence should be specifically highlighted. That opens possibility for Zika persistence in normal cells upon application as vaccine

Author Response

We thank the reviewer for the suggestions, the text has been modified as requested.

Author Response File: Author Response.docx

Reviewer 2 Report

The review by Dr Francipane and peers aims to describe the current state-of-the-art about the Zika virus as new therapeutic option for patients with glioblastoma.

The review is well-organized and written, and comprehensive. Authors describe the possibility to use the virus oncotherapy in the treatment of glioblastoma through a deep discussion of the rationale for both malignant gliomas and Zika virus.

The review ha scientific soundness and is supported by appropriate and adequate references.

The topic is interesting and of novelty, due to the possibility to consider Zika virus as potential target for therapy in patients with GBM or recurrences. It may improve the current state-of-the-art in the field of new therapies against the most malignant brain tumours in adults.

Minor points:

  1. A revision of the English language is advisable. Some misspellings should be amended.

Author Response

We thank the reviewer for the positive comments. The paper has been revised by a language service, and a certificate has been included.

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

all comments are being adressed

Back to TopTop